Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function
- PMID: 12923179
- DOI: 10.1074/jbc.M308041200
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function
Abstract
Lewy bodies are intracellular fibrillar inclusions composed of alpha-synuclein. They constitute the pathological hallmark of Parkinson's disease, dementia with Lewy bodies, and other neurodegenerative diseases. Although the majority of Lewy bodies are stained for ubiquitin by immunohistochemistry, the substrate for this modification is poorly understood. Insoluble, urea-soluble alpha-synuclein was separated from soluble fractions and subjected to two-dimensional gel electrophoresis to further characterize pathogenic alpha-synuclein species from disease brains. By using this approach, we found that in sporadic Lewy body diseases a highly modified, disease-associated 22-24-kDa alpha-synuclein species is ubiquitinated. Conjugation of one, two, and, to a lesser extent, three ubiquitins was detected. This 22-24-kDa alpha-synuclein species represents partly phosphorylated protein. Furthermore, no generalized impairment of the proteolytic activity of the proteasome was detected in brain regions with Lewy body pathology. Because unmodified alpha-synuclein is degraded by the proteasome in a ubiquitin-independent manner, these data suggest that accumulation of modified 22-24-kDa alpha-synuclein is a disease-specific event which may overwhelm the proteolytic system, leading to aberrant ubiquitination. Accordingly, carboxyl-terminal-truncated alpha-synuclein, presumably the result of aberrant proteolysis, is found only in association with alpha-synuclein aggregates.
Similar articles
-
Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies.J Neurochem. 2004 Feb;88(4):800-12. doi: 10.1046/j.1471-4159.2003.02168.x. J Neurochem. 2004. PMID: 14756800
-
Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons.Neuroscience. 2001;104(3):901-12. doi: 10.1016/s0306-4522(01)00113-0. Neuroscience. 2001. PMID: 11440819
-
Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies.Acta Neuropathol. 2001 Oct;102(4):329-34. doi: 10.1007/s004010100369. Acta Neuropathol. 2001. PMID: 11603807
-
[Recent neuropathology of parkinsonian syndromes].Rev Neurol (Paris). 2003 May;159(5 Pt 2):3S11-8. Rev Neurol (Paris). 2003. PMID: 12773883 Review. French.
-
Alpha synuclein in neurodegenerative disorders: murderer or accomplice?Nat Med. 1998 Jul;4(7):755-7. doi: 10.1038/nm0798-755. Nat Med. 1998. PMID: 9662355 Review. No abstract available.
Cited by
-
Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.Brain. 2015 Jun;138(Pt 6):1642-57. doi: 10.1093/brain/awv040. Epub 2015 Mar 1. Brain. 2015. PMID: 25732184 Free PMC article.
-
Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities.J Neurosci. 2012 Oct 24;32(43):15227-42. doi: 10.1523/JNEUROSCI.3545-12.2012. J Neurosci. 2012. PMID: 23100443 Free PMC article.
-
SUMOylation in α-Synuclein Homeostasis and Pathology.Front Aging Neurosci. 2020 Jun 25;12:167. doi: 10.3389/fnagi.2020.00167. eCollection 2020. Front Aging Neurosci. 2020. PMID: 32670048 Free PMC article. Review.
-
Ubiquitination of alpha-synuclein filaments by Nedd4 ligases.PLoS One. 2018 Jul 18;13(7):e0200763. doi: 10.1371/journal.pone.0200763. eCollection 2018. PLoS One. 2018. PMID: 30021006 Free PMC article.
-
Pathological proteins in Parkinson's disease: focus on the proteasome.J Mol Neurosci. 2004;24(3):425-42. doi: 10.1385/JMN:24:3:425. J Mol Neurosci. 2004. PMID: 15655264 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous